A study conducted by Neff Ehninger and coworkers showed that rapamycin extends one’s life span, although it has limited impact on aging. In his paper, Mikhail Blagosklonny proves that rapamycin slows aging and facilitates life extension despite its direct anti-cancer processes. Aging is an aggressive increase of the potential of death by age. Diseases like cardiovascular diseases, hypertension, macular degeneration, Alzheimer and cancer are biomarkers of aging. Most elderly people die from age-related diseases. Mikhail states that cellular aging, which is in part MTOR-dependant, should be linked to aging. Growth factors, nutrients, hormones and oxygen initiate MTOR pathway, stimulating certain functions of differentiated cells. However, interventions of cancer, an age-related disease, slows aging with its interventions like calorie restriction. Rapamycin, a popular cancer drug and a TOR inhibitor, slows aging. From mammals to yeast, Rapamycin seeks to extend lifespan of all species. In addition, rapamycin suppresses geroconversion, which is a cellular-based organismal aging. View Mikhail’s profile on Google Scholar
About Mikhail Blagosklonny
Mikhail Blagosklonny is a household name in the field of cancer and aging research. Being the professor of oncology at Roswell Park Cancer Institute, Mikhail spends most of his time researching about cancer and aging. Previously, he worked for Ordway Research Institute, Albany, as a senior scientist. Before joining Ordway, Mikhail worked for the New York Medical College as an associate professor of medicine. His research interests include cell cycle, apoptosis, signal transduction, mitosis, aging, tumor and oncogenes, and targeted anti-cancer therapies.
Mikhail Blagosklonny is known for his Hyperfunction theory, which involves chemotherapeutic engineering and cell cyclotherapy for cancer treatment. He is also known to be an advocate for the use of rapamycin in cancer treatment. To date, he has authored over 270 publications. He is also heavily involved in editorial activities of scientific papers. Mikhail is the co-founder and editor-in-chief of renowned scientific journals such as Oncotarget, Oncoscience, and Aging. Blagosklonny serves as an associate editor for Cancer Research, Cancer Biology and Therapy, International Journal of Pathology, Cell Death and Differentiation Autophagy, and PLOS ONE. Notably, Mikhail has made commendable contributions to study of cancer and aging.